An AstraZeneca-funded study found that only a relatively small proportion change their severe asthma prescription or discontinue its use. The study of over 3,500 patients found 79% (2,791) continued their first prescription, while 10.2% (356) stopped its use, and 10.8% (384) switched prescriptions.
Investigators sought to characterize the real-world use of biologics and switching patterns among patients with severe asthma globally. The study sample was a historical cohort of adults with severe asthma who were treated with a biologic, including 3531 patients from 11 countries (Bulgaria, Canada, Denmark, Greece, Italy, Japan, Kuwait, South Korea, Spain,
United Kingdom, and US) enrolled in either the International Severe Asthma Registry from 2015 to 2020 or the CHRONICLE Study ClinicalTrials.gov Identifier: NCT03373045) from 2018 to 2020. Participants were also required to have a minimum follow-up of 6 months after biologic initiation.
Get the full story at pulmonologyadvisor.com.
severe asthma prescription
Go To Source For Respiratory Therapy Coverage
RT delivers in-depth coverage of the clinical, regulatory, and technology landscape for respiratory therapy—and reaches more than 28,000 key decision-makers and influencers. As one of healthcare’s most important data companies, we facilitate the rapid adoption of medical devices and practice management tools into the industry.
Go To Source For Respiratory Therapy Coverage RT delivers in-depth coverage of the clinical, regulatory, and technology landscape for respiratory therapy—and reaches more than 28,000 key decision-makers and influencers. As one of healthcare’s most important data companies, we facilitate the rapid adoption of medical devices and practice management tools into the industry.
